{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:50:07Z","timestamp":1760986207295,"version":"3.44.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.amjmed.2023.09.018","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T02:05:57Z","timestamp":1697076357000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-Centered Heart Failure Therapy"],"prefix":"10.1016","volume":"137","author":[{"given":"Rohan","family":"Samson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre V.","family":"Ennezat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-9821","authenticated-orcid":false,"given":"Thierry H. Le","family":"Jemtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.amjmed.2023.09.018_bib0001","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"10244","key":"10.1016\/j.amjmed.2023.09.018_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"10367","key":"10.1016\/j.amjmed.2023.09.018_bib0003","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.018_bib0005","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/jcm12031020","article-title":"Heart failure pharmacological management: gaps and current perspectives","volume":"12","author":"Severino","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.018_bib0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"issue":"9372","key":"10.1016\/j.amjmed.2023.09.018_bib0007","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cardfail.2021.08.008","article-title":"Treatment persistence of renin-angiotensin-aldosterone-system inhibitors over time in heart failure with reduced ejection fraction","volume":"28","author":"Vaduganathan","year":"2022","journal-title":"J Card Fail"},{"issue":"22","key":"10.1016\/j.amjmed.2023.09.018_bib0009","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.018_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.018_bib0012","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jchf.2022.04.013","article-title":"Tolerability of sacubitril\/valsartan in patients with advanced heart failure: analysis of the LIFE trial run-in","volume":"10","author":"Vader","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.018_bib0014","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.98.12.1184","article-title":"Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials","volume":"98","author":"Lechat","year":"1998","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.018_bib0015","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"9169","key":"10.1016\/j.amjmed.2023.09.018_bib0016","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.amjmed.2023.09.018_bib0017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0018","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.018_bib0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CRD.0000000000000068","article-title":"Reverse remodeling in systolic heart failure","volume":"23","author":"Saraon","year":"2015","journal-title":"Cardiol Rev"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.018_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1388-9842(00)00150-1","article-title":"Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with 'classical' clinical diagnosis of idiopathic dilated cardiomyopathy","volume":"3","author":"Cicoira","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.018_bib0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cardfail.2003.10.002","article-title":"Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy","volume":"10","author":"Cioffi","year":"2004","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mhj.2003.105","article-title":"Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance","volume":"145","author":"Metra","year":"2003","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.amjmed.2023.09.018_bib0023","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.018_bib0024","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.amjcard.2014.02.028","article-title":"Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy","volume":"113","author":"Zou","year":"2014","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.018_bib0025","first-page":"405","article-title":"Prevalence and clinical predictors of reverse remodeling in patients with dilated cardiomyopathy","volume":"16","author":"Arad","year":"2014","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0026","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ehf2.14303","article-title":"Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction","volume":"10","author":"Liu","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.018_bib0027","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2018.05.004","article-title":"Heart failure with improved ejection fraction: is it possible to escape one's past?","volume":"6","author":"Gulati","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.018_bib0028","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCHEARTFAILURE.114.001957","volume":"8","author":"Lala","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11897-015-0273-5","article-title":"Current approach to decongestive therapy in acute heart failure","volume":"12","author":"Martens","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.amjmed.2023.09.018_bib0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","article-title":"Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure","volume":"258","author":"Rubio-Gracia","year":"2018","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.018_bib0031","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","article-title":"Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial","volume":"34","author":"Ambrosy","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2023.09.018_bib0032","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2022.12.057","article-title":"Prognostic implications of post-discharge hemodynamic congestion assessed by peripheral venous pressure among patients discharged from acute heart failure","volume":"374","author":"Matsuto","year":"2023","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.018_bib0033","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurjhf\/hfq045","article-title":"Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine","volume":"12","author":"Gheorghiade","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.amjmed.2023.09.018_bib0034","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.amjmed.2023.09.018_bib0035","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.amjmed.2023.09.018_bib0036","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.018_bib0038","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0039","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.018_bib0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.120.052048","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with heart failure with reduced ejection fraction: the heart and kidney working better together","volume":"143","author":"Carnicelli","year":"2021","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.amjmed.2023.09.018_bib65","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0041","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1002\/ehf2.14086","article-title":"Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial","volume":"9","author":"Monzo","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.018_bib0042","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.018_bib0043","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ejhf.2952","article-title":"Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial","volume":"25","author":"Monzo","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"10.1016\/j.amjmed.2023.09.018_bib0044","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0046","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0047","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.018_bib0048","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.018_bib0050","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.018_bib0051","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jchf.2020.03.009","article-title":"Acute kidney function declines in the context of decongestion in acute decompensated heart failure","volume":"8","author":"McCallum","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0052","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0053","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ejhf.2384","article-title":"Worsening renal function in acute heart failure in the context of diuretic response","volume":"24","author":"Emmens","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0054","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.688","article-title":"Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia","volume":"19","author":"Rossignol","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.018_bib0055","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0056","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ejhf.2743","article-title":"Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey","volume":"25","author":"Fauvel","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.018_bib0057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11897-021-00538-7","article-title":"Impact of loop diuretic on outcomes in patients with heart failure and reduced ejection fraction","volume":"19","author":"Antonietta","year":"2022","journal-title":"Curr Heart Fail Rep"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.018_bib0058","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1002\/ehf2.14157","article-title":"Association of congestion with worsening renal function in acute decompensated heart failure according to age","volume":"9","author":"Odajima","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.018_bib0059","first-page":"1097","article-title":"Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial","volume":"35","author":"Greene","year":"2019","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.018_bib0060","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring","volume":"7","author":"Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjmed.2023.09.018_bib0061","doi-asserted-by":"crossref","DOI":"10.1177\/11795468221133607","article-title":"'A missed therapeutic opportunity? SGLT-2 inhibitor use in general medicine patients with heart failure: a retrospective audit of admissions to a tertiary health service'","volume":"16","author":"Perera","year":"2022","journal-title":"Clin Med Insights Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.018_bib0062","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:32:09Z","timestamp":1757583129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323006162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0002934323006162"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.018","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Centered Heart Failure Therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}